J Nat Prod . Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

[tetano]

J Nat Prod


. 2022 Jan 10.
doi: 10.1021/acs.jnatprod.1c00946. Online ahead of print.
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants


Richard B van Breemen ¹ , Ruth N Muchiri ¹ , Timothy A Bates ² , Jules B Weinstein ² , Hans C Leier ² , Scotland Farley ² , Fikadu G Tafesse ²



Affiliations

• PMID: 35007072
• DOI: 10.1021/acs.jnatprod.1c00946

Abstract

As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.

[sharon sanders]

bump this